膀胱移行细胞癌中hepaCAM外显子2甲基化抑制hepaCAM表达
|
摘要
第一部分hepaCAM在TCCB中表达及临床意义
目的探讨肝细胞粘附分子(hepatocyte cell adhesion molecule, hepaCAM)在膀胱移行细胞癌(transitional carcinomal of the bladder, TCCB)中表达及与临床病理参数关系。
方法采用半定量RT-PCR法检测hepaCAM基因在膀胱癌细胞株(T24、BIU-87)和55例TCCB组织及癌旁组织中hepaCAM mRNA表达、并分析其与临床病理参数间的关系。
结果hepaCAM mRNA在膀胱癌细胞株(T24、BIU-87)中表达缺失,hepaCAM mRNA在TCCB组织中的表达水平明显低于癌旁组织(P<0.001), hepaCAM mRNA表达与TCCB临床分期有关(P<0.05),而与病理分级、性别、年龄无关。
结论hepaCAM mRNA在膀胱癌细胞株(T24、BIU-87)及TCCB组织中表达明显下降或缺失,且与临床分期有关,推测hepaCAM可能是TCCB新的候选抑癌基因。
第二部分TCCB中hepaCAM基因外显子2甲基化状态分析
目的检测膀胱癌细胞株(T24、BIU-87)和TCCB组织中hepaCAM外显子2的甲基化情况,探讨hepaCAM基因在TCCB中表达下调是否与hepaCAM外显子2的甲基化有关,从表观遗传学角度探讨膀胱癌发病的机制。
方法采用甲基化敏感性限制性内切酶PCR法检测膀胱癌细胞株(T24、BIU-87)和TCCB组织中hepaCAM外显子2甲基化情况,分析其与临床病理参数之间的关系,并探讨TCCB组织中hepaCAM外显子2甲基化与hepaCAM mRNA表达之间的关系。
结果甲基化敏感性限制性内切酶PCR检测发现膀胱癌细胞株(T24、BIU-87)和52.7%(29/55)TCCB组织中存在hepaCAM外显子2甲基化,而相应的癌旁组织甲基化率为5.5%(3/55),hepaCAM外显子2甲基化率在癌及癌旁组织中的差异具有显著统计学意义(P<0.001)。hepaCAM外显子2甲基化与hepaCAM mRNA表达呈负相关(r=﹣0.403,P<0.05)。
结论hepaCAM外显子2甲基化是导致TCCB组织中hepaCAM mRNA表达下调的主要原因之一,为探讨揭示TCCB发生发展机制提供新的理论依据。
第三部分DNA甲基化调控膀胱癌细胞株hepaCAM表达的机制目的探讨5-氮2-脱氧胞苷(5-Aza-CdR)(DNA甲基化转移酶抑制剂)对膀胱癌细胞株(T24、BIU-87)中hepaCAM表达的调控作用及对细胞生长增殖的影响。进一步探讨hepaCAM外显子2甲基化导致hepaCAM下调TCCB发生的机制。
方法分别用不同药物浓度的5-Aza-CdR处理T24和BIU-87细胞株,MTT法检测5-Aza-CdR对细胞增殖的影响,采用甲基化敏感性限制性内切酶PCR法hepaCAM基因外显子2区域甲基化状态,RT-PCR法检测5-Aza-CdR处理前后hepaCAM mRNA的表达情况。
结果5-Aza-CdR具有抑制T24和BIU-87细胞增殖作用。未经5-Aza-CdR处理的T24和BIU-87细胞hepaCAM mRNA不表达,且hepaCAM基因外显子2区高甲基化;经5-Aza-CdR处理后T24和BIU-87细胞hepaCAM基因表达,细胞中hepaCAM基因外显子2区甲基化状态得到逆转。
结论5-Aza-CdR能有效逆转膀胱癌T24和BIU-87细胞hepaCAM基因外显子2的异常甲基化,从而诱导hepaCAM基因的重新表达,抑制肿瘤细胞生长,结果表明:hepaCAM外显子2甲基化是促进hepaCAM表达下调从而导致膀胱癌发生的新的分子机制,为TCCB治疗提供新的思路。
PART ONE: THE EXPRESSION OF HEPACAM IN TCCB
Objective: To explore the expression of hepaCAM (hepatocyte cell adhesion molecule) mRNA in TCCB(transitional carcinomal of the bladder)and the relationship between hepaCAM mRNA and the clinical pathology parameters.
Methods: To detect expression of hepaCAM mRNA by RT-PCR in bladder cancer cell lines (T24,BIU-87), 55 TCCB tissues and corresponding adjacent tissues and analyze the relationship between hepaCAM mRNA and the clinical pathology parameters.
Results: The expression of hepaCAM mRNA was deficient in bladder cancer cell lines(T24,BIU-87). the expression level of hepaCAM in TCCB tissues was lower than that in adjacent tissues (P<0.001). No significant difference of hepaCAM mRNA was detected in the pathological grade, gender and age, but there was statistically significant differences in clinical stage (P<0.05).
Conclusion: The expression of hepaCAM mRNA is obviously decrease or deficient in TCCB tissues and bladder cancer cell lines (T24,BIU-87). HepaCAM may be a putative tumor suppressor gene in TCCB.
PART TWO THE ANALYSIS OF THE MEHYLATION STATUS OF HEPACAM EXON2
Objective: To detect the methylation status of hepaCAM exon 2 in bladder cancer cell lines(T24,BIU-87) and TCCB tissues and explore the potential mechanism of the down-regulation of hepaCAM expression in TCCB.
Methods: We use the methylation-specific restriction-PCR-assay to detect the methylation status of hepaCAM exon 2 in TCCB and bladder caner cell lines(T24,BIU-87), analyze the relationship between the methylation of hepaCAM exon 2 and the clinical pathology parameters and explore the relationship between the methylation of hepaCAM exon 2 and expression of hepaCAM mRNA from the perspective of epigenetics.
Results: The methylation status of hepaCAM exon 2 was observed in bladder caner cell lines(T24,BIU-87) and 29 of 55 primary cancers, whereas in the adjacent tissues by methylation-specific restriction-PCR-assay , only 3 of 55 cases exhibited hepaCAM exon 2 methylation, and the methylation rate of hepaCAM exon 2 was significant higher in TCCB than that in adjacent renal tissues(52.7% vs. 5.5%,P<0.001). the methylation of hepaCAM exon 2 was negatively correlated to the expression of hepaCAM(r=-0.403,P<0.05).
Conclusion: The methylation of hepaCAM exon 2 may be one important reasion for down-regulation of hepaCAM expression in TCCB. The study of hepaCAM methylation provides a new theoretical evidence for the mechanism of the occurrence and development of TCCB.
PART THREE THE MECHANISM OF DNA METHYLATION REFULATION HEPACM EXPRESSION IN BLADDER CANCER CELLS
Objective: The study is to explore the transcription regulation 5-Aza-2-deoxycytidine (5-Aza-CdR) on hepaCAM tumor suppressor gene in bladder cancer cell lines(T24,BIU-87)and to investigate its effect on the growth of T24 and BIU-87 cells and to further explore the mechanism of hepaCAM exon2 resulting in down-regulation of hepaCAM expression in TCCB.
Methods: T24 and BIU-87 cell lines were separately treated with different dose of 5-Aza-CdR.MTT was used to detect the effect of 5-Aza-CdR on the growth of T24 and BIU-87 cells. The status of hepaCAM exon 2 methylation was analyzed using methylation-specific restriction-PCR-assay. RT-PCR was used to examine the expression of hepaCAM gene in before and after treated T24 and BIU-87 cells.
Results: The growth of the T24 and BIU-87 cells was suppressed by treatment with 5-Aza-CdR.Before 5-Aza-CdR treatment, hypermethylation of hepaCAM exon 2 exised and hepaCAM mRNA was not expressed in T24 and BIU-87 cells. HepaCAM mRNA was re-expressed and the methylation status of hepaCAM exon 2 was obviously reversed after treatment with 5-Aza-CdR.
Conclusion: 5-Aza-CdR may effectively cause the demethyaltion of hepaCAM exon 2, induce the expression of hepaCAM, and inhibit the growth of tumor cells.The result suggest that the methylation of hepaCAM exon2 is a new mechanism of resulting in down-regulation of hepaCAM expression in TCCB.This provides new ideas for the treatment of TCCB.
目的探讨肝细胞粘附分子(hepatocyte cell adhesion molecule, hepaCAM)在膀胱移行细胞癌(transitional carcinomal of the bladder, TCCB)中表达及与临床病理参数关系。
方法采用半定量RT-PCR法检测hepaCAM基因在膀胱癌细胞株(T24、BIU-87)和55例TCCB组织及癌旁组织中hepaCAM mRNA表达、并分析其与临床病理参数间的关系。
结果hepaCAM mRNA在膀胱癌细胞株(T24、BIU-87)中表达缺失,hepaCAM mRNA在TCCB组织中的表达水平明显低于癌旁组织(P<0.001), hepaCAM mRNA表达与TCCB临床分期有关(P<0.05),而与病理分级、性别、年龄无关。
结论hepaCAM mRNA在膀胱癌细胞株(T24、BIU-87)及TCCB组织中表达明显下降或缺失,且与临床分期有关,推测hepaCAM可能是TCCB新的候选抑癌基因。
第二部分TCCB中hepaCAM基因外显子2甲基化状态分析
目的检测膀胱癌细胞株(T24、BIU-87)和TCCB组织中hepaCAM外显子2的甲基化情况,探讨hepaCAM基因在TCCB中表达下调是否与hepaCAM外显子2的甲基化有关,从表观遗传学角度探讨膀胱癌发病的机制。
方法采用甲基化敏感性限制性内切酶PCR法检测膀胱癌细胞株(T24、BIU-87)和TCCB组织中hepaCAM外显子2甲基化情况,分析其与临床病理参数之间的关系,并探讨TCCB组织中hepaCAM外显子2甲基化与hepaCAM mRNA表达之间的关系。
结果甲基化敏感性限制性内切酶PCR检测发现膀胱癌细胞株(T24、BIU-87)和52.7%(29/55)TCCB组织中存在hepaCAM外显子2甲基化,而相应的癌旁组织甲基化率为5.5%(3/55),hepaCAM外显子2甲基化率在癌及癌旁组织中的差异具有显著统计学意义(P<0.001)。hepaCAM外显子2甲基化与hepaCAM mRNA表达呈负相关(r=﹣0.403,P<0.05)。
结论hepaCAM外显子2甲基化是导致TCCB组织中hepaCAM mRNA表达下调的主要原因之一,为探讨揭示TCCB发生发展机制提供新的理论依据。
第三部分DNA甲基化调控膀胱癌细胞株hepaCAM表达的机制目的探讨5-氮2-脱氧胞苷(5-Aza-CdR)(DNA甲基化转移酶抑制剂)对膀胱癌细胞株(T24、BIU-87)中hepaCAM表达的调控作用及对细胞生长增殖的影响。进一步探讨hepaCAM外显子2甲基化导致hepaCAM下调TCCB发生的机制。
方法分别用不同药物浓度的5-Aza-CdR处理T24和BIU-87细胞株,MTT法检测5-Aza-CdR对细胞增殖的影响,采用甲基化敏感性限制性内切酶PCR法hepaCAM基因外显子2区域甲基化状态,RT-PCR法检测5-Aza-CdR处理前后hepaCAM mRNA的表达情况。
结果5-Aza-CdR具有抑制T24和BIU-87细胞增殖作用。未经5-Aza-CdR处理的T24和BIU-87细胞hepaCAM mRNA不表达,且hepaCAM基因外显子2区高甲基化;经5-Aza-CdR处理后T24和BIU-87细胞hepaCAM基因表达,细胞中hepaCAM基因外显子2区甲基化状态得到逆转。
结论5-Aza-CdR能有效逆转膀胱癌T24和BIU-87细胞hepaCAM基因外显子2的异常甲基化,从而诱导hepaCAM基因的重新表达,抑制肿瘤细胞生长,结果表明:hepaCAM外显子2甲基化是促进hepaCAM表达下调从而导致膀胱癌发生的新的分子机制,为TCCB治疗提供新的思路。
PART ONE: THE EXPRESSION OF HEPACAM IN TCCB
Objective: To explore the expression of hepaCAM (hepatocyte cell adhesion molecule) mRNA in TCCB(transitional carcinomal of the bladder)and the relationship between hepaCAM mRNA and the clinical pathology parameters.
Methods: To detect expression of hepaCAM mRNA by RT-PCR in bladder cancer cell lines (T24,BIU-87), 55 TCCB tissues and corresponding adjacent tissues and analyze the relationship between hepaCAM mRNA and the clinical pathology parameters.
Results: The expression of hepaCAM mRNA was deficient in bladder cancer cell lines(T24,BIU-87). the expression level of hepaCAM in TCCB tissues was lower than that in adjacent tissues (P<0.001). No significant difference of hepaCAM mRNA was detected in the pathological grade, gender and age, but there was statistically significant differences in clinical stage (P<0.05).
Conclusion: The expression of hepaCAM mRNA is obviously decrease or deficient in TCCB tissues and bladder cancer cell lines (T24,BIU-87). HepaCAM may be a putative tumor suppressor gene in TCCB.
PART TWO THE ANALYSIS OF THE MEHYLATION STATUS OF HEPACAM EXON2
Objective: To detect the methylation status of hepaCAM exon 2 in bladder cancer cell lines(T24,BIU-87) and TCCB tissues and explore the potential mechanism of the down-regulation of hepaCAM expression in TCCB.
Methods: We use the methylation-specific restriction-PCR-assay to detect the methylation status of hepaCAM exon 2 in TCCB and bladder caner cell lines(T24,BIU-87), analyze the relationship between the methylation of hepaCAM exon 2 and the clinical pathology parameters and explore the relationship between the methylation of hepaCAM exon 2 and expression of hepaCAM mRNA from the perspective of epigenetics.
Results: The methylation status of hepaCAM exon 2 was observed in bladder caner cell lines(T24,BIU-87) and 29 of 55 primary cancers, whereas in the adjacent tissues by methylation-specific restriction-PCR-assay , only 3 of 55 cases exhibited hepaCAM exon 2 methylation, and the methylation rate of hepaCAM exon 2 was significant higher in TCCB than that in adjacent renal tissues(52.7% vs. 5.5%,P<0.001). the methylation of hepaCAM exon 2 was negatively correlated to the expression of hepaCAM(r=-0.403,P<0.05).
Conclusion: The methylation of hepaCAM exon 2 may be one important reasion for down-regulation of hepaCAM expression in TCCB. The study of hepaCAM methylation provides a new theoretical evidence for the mechanism of the occurrence and development of TCCB.
PART THREE THE MECHANISM OF DNA METHYLATION REFULATION HEPACM EXPRESSION IN BLADDER CANCER CELLS
Objective: The study is to explore the transcription regulation 5-Aza-2-deoxycytidine (5-Aza-CdR) on hepaCAM tumor suppressor gene in bladder cancer cell lines(T24,BIU-87)and to investigate its effect on the growth of T24 and BIU-87 cells and to further explore the mechanism of hepaCAM exon2 resulting in down-regulation of hepaCAM expression in TCCB.
Methods: T24 and BIU-87 cell lines were separately treated with different dose of 5-Aza-CdR.MTT was used to detect the effect of 5-Aza-CdR on the growth of T24 and BIU-87 cells. The status of hepaCAM exon 2 methylation was analyzed using methylation-specific restriction-PCR-assay. RT-PCR was used to examine the expression of hepaCAM gene in before and after treated T24 and BIU-87 cells.
Results: The growth of the T24 and BIU-87 cells was suppressed by treatment with 5-Aza-CdR.Before 5-Aza-CdR treatment, hypermethylation of hepaCAM exon 2 exised and hepaCAM mRNA was not expressed in T24 and BIU-87 cells. HepaCAM mRNA was re-expressed and the methylation status of hepaCAM exon 2 was obviously reversed after treatment with 5-Aza-CdR.
Conclusion: 5-Aza-CdR may effectively cause the demethyaltion of hepaCAM exon 2, induce the expression of hepaCAM, and inhibit the growth of tumor cells.The result suggest that the methylation of hepaCAM exon2 is a new mechanism of resulting in down-regulation of hepaCAM expression in TCCB.This provides new ideas for the treatment of TCCB.
引文
[1] Colombel M, Soloway M, Akaza H, et al. Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer[J]. European Urology 2008,7:618-626
[2] Reuter VE:The pathology of bladder cancer[J]. Urology 2006; 67:11-17
[3] Kirkali Z, Chan T, Manoharan M, et al. Bladder Cancer: Epidemiology, staging and grading, and diagnosis[J]. Urology 2005, 66:24-34
[4] Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy[J]. Eur Urol 2009 ,56:430-442
[5] Moh MC, Lee LH, Shen S. Cloning and characterization of hepaCAM,a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma[J]. Hepatol 2005, 42: 833 - 841
[6] Lee LH, Moh MC, Zhang T, et al. The Immunoglobulin-Like Cell Adhesion Molecule HepaCAM Induces Differentiation of Human Glioblastoma U373-MG Cells[J]. Journal of Cellular Biochemistry 2009,107: 1129-1138
[7] Moh MC, Zhang T, Lee LH, et al. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells[J]. Carcinogenesis 2008,29: 2298-2305
[8] Xun C, Luo C, Wu X, et al. Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma[J]. Urology 2010,75(4):828-834
[9] Christoph F, Weikert S, Kempkensteffen C, et al.Regularly methylated novel pro-apop-totic genes associated with recurrence in transitional cell carcinoma of the bladder[J]. Int J Cancer 2006,119:1396-1402
[10] Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer[J]. Nat Rev Genet 2002; 3:415-428
[11] Jones PA, Laird PW: Cancer epigenetics comes of age[J]. Nat Genet 1999,21: 163-167
[12] [Tokita T, Maesawa C, Kimura T, et al. Methylation status of the SOCS3 gene inhuman malignant melanomas[J]. Int J Oncol 2007,30:689-694
[13] Tischoff I, Hengge UR, Vieth M, et al. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma[J]. Gut 2007,56:1047-1053
[14] Ortmann CA, Burchert A, Nitsche A, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region[J]. Nucleic Acids Research, 2005,33:6895-6905
[15] Catto JW, Azzouzi AR, Rehman I,et al; Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma[J]. J Clin Oncol, 2005, 23(13):2903-2910
[16] Dulaimi E, Uzzo RG, Greenberg RE,et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel[J]. Clin Cancer Res, 2004, 10(6):1887-93
[17] Kawamoto K, Enokida H, Gotanda T, et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer[J]. Biochem Biophys Res Commun, 2006, 339(3):790-796
[18] Friedrich MG, Chandrasoma S, Siegmund KD, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma[J]. Eur J Cancer, 2005, 41(17):2769-2778
[19] Kim WJ, Kim EJ, Jeong P, et al.RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors[J]. Cancer Res, 2005, 65(20): 9347-9354
[20]元云飞,李锦清,杨祖立,等.肿瘤相关基因过甲基化的研究进展[J].癌症, 2002,21(11):1267-1277
[21] Moh, M C, TIAN Q, Zhang T, et al. The immunoglobulin-like cell adhesion molecule hepaCAM modulates cell adhesion and motility through direct interaction with the actin cytoskeleton[J]. Journal of Cell physiology 2009, 219(2):382-391.
[22]荀春华,罗春丽,吴小候,等. HepaCAM基因转染对肾癌细胞侵袭活性的影响[J].肿瘤,2008,28(12):1029-1033
[23] Horikawa Y, Sugano K, Shigyo M, et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ[J]. J Urol 2003, 169(4):1541-1545
[24] Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy[J]. Nature, 2004, 429(6990):457-463
[1] Vertino PM ,Yen RW, Gao J ,et al. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA(cytosine- 5) - methyltransferase1. Mol Cell Biol ,1996 ,16 (8) ;45-55
[2] Bird A. DNA methylation patterns and epigenetic memory[J].Genes Dev,2002,16 (1):6-21
[3] Siyang Zhang, Dawei Guo, Lili Jiang, et al. SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC Cancer, 2008, 8: 150
[4]彭正良.甲状腺肿瘤相关基因甲基化研究进展.国外医学·生理、病理科学与临床分册.2005,25(2):126-129
[5] Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression [J]. Nature, 2004,432 (7015 ):307-315
[6] Chan MW, Chan LW,et a1. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients[J].Int J Cancer. 2003,104(5):611-615
[7]米军,段建敏,岳中瑾,等.膀胱癌DBCCR1、p16、p15、p14基因甲基化检测的意义[J].中华泌尿外科杂志,2006,27(6):427-429
[8] Hellwinkel, Merab Kedia, Hendrik Isbarn, et a1. Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours[J]. Bju International,2007,101:753–757.
[9] Horikawa Y, Sugano K, Shigyo M.et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ[J]. J Urol. 2003 ,169(4):1541-1545
[10] Ribeiro-Filho LA, Franks J, Sasaki M, et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer[J]. Mol Carcinog, 2002, 34(4):187-198
[11] Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res, 2005,65(20):9347-9354
[12] Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylationprofile of bladder cancer and its relationship to clinicopathological features [J]. Cancer Res,2001,61(24) ;8659-8663
[13] Aleman A, Adrien L, Lopez-Serra L,et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays[J]. Br J Cancer, 2008, 98(2):466-473
[14] Chan MW, Chan LW, Tang NL, et al. Hypermethyaltion of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients[J]. Clin. Cancer Res, 2002,8(2) ;464-470
[15] Sathyanarayana UG, Maruyama R, Padar A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes[J]. Cancer Res, 2004, 64 (4) :1425 -1430
[16] Urakami S, Shiina H, Enokida H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection[J]. Clin.Cancer Res,2006,12(7Pt 1) :2109-2116
[17] Kang GH, Lee S, Kim JS, et a1. Profile of aberrant CpG island methyhlation along the multistep pathway of gastric carcinogenesis[J]. Lab Invest, 2003, 83(5):635-641
[18] Czerniak B, Herz F, Wersto RP, Koss LG. Asymmetric distribution of oncogene products at mitosis[J]. Proc.Natl Acad. Sci. USA,1992,82(11):4860-4863
[19] Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene[J]. N.Engl.J.Med,1993,329(18):1318-1327
[20] Al-Sukhun S, Hussain M, Molecular biology of transitional cell carcinoma[J]. Crit.Rev.Oncol.Hematol,2003 ,47(2):181-193
[21] Orntoft TF, Wolf H. Molecular alterations in bladder cancer[J]. Urol. Res, 1998, 26 (4):223-233
[22] Jones PA, Baylin SB. The fundamental role of epigenetic events in cacer[J]. Nat.Rev.Genet,2002,3(6):415-428
[23] Jones PA, Larid PW. Cancer epigenetics comes of age [J]. Nat. Genet. 1999, 21 (2): 163-167
[24] Herman JG, Baylin SB.Gene silencing in cancer in association with promoter hypermethylation[J]. N.Engl.J.Med,2003,349(21):2042-2054
[25] Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor [J]. J.Urol, 2008, 180 (3): 1141-1145.
[26] Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients[J]. Clin. Cancer Res,2003,10(22):7457-7465
[27] Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methyaltion of multiople genes in urine DNA and bladder cancer detection[J].J.Natl Cancer Inst,2006,98(14):996-1004
[28] Yates DR, Rehman I,Meuth M,Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign contrls[J]. Oncogene,2006,25(13):1984-1988
[2] Reuter VE:The pathology of bladder cancer[J]. Urology 2006; 67:11-17
[3] Kirkali Z, Chan T, Manoharan M, et al. Bladder Cancer: Epidemiology, staging and grading, and diagnosis[J]. Urology 2005, 66:24-34
[4] Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy[J]. Eur Urol 2009 ,56:430-442
[5] Moh MC, Lee LH, Shen S. Cloning and characterization of hepaCAM,a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma[J]. Hepatol 2005, 42: 833 - 841
[6] Lee LH, Moh MC, Zhang T, et al. The Immunoglobulin-Like Cell Adhesion Molecule HepaCAM Induces Differentiation of Human Glioblastoma U373-MG Cells[J]. Journal of Cellular Biochemistry 2009,107: 1129-1138
[7] Moh MC, Zhang T, Lee LH, et al. Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells[J]. Carcinogenesis 2008,29: 2298-2305
[8] Xun C, Luo C, Wu X, et al. Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma[J]. Urology 2010,75(4):828-834
[9] Christoph F, Weikert S, Kempkensteffen C, et al.Regularly methylated novel pro-apop-totic genes associated with recurrence in transitional cell carcinoma of the bladder[J]. Int J Cancer 2006,119:1396-1402
[10] Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer[J]. Nat Rev Genet 2002; 3:415-428
[11] Jones PA, Laird PW: Cancer epigenetics comes of age[J]. Nat Genet 1999,21: 163-167
[12] [Tokita T, Maesawa C, Kimura T, et al. Methylation status of the SOCS3 gene inhuman malignant melanomas[J]. Int J Oncol 2007,30:689-694
[13] Tischoff I, Hengge UR, Vieth M, et al. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma[J]. Gut 2007,56:1047-1053
[14] Ortmann CA, Burchert A, Nitsche A, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region[J]. Nucleic Acids Research, 2005,33:6895-6905
[15] Catto JW, Azzouzi AR, Rehman I,et al; Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma[J]. J Clin Oncol, 2005, 23(13):2903-2910
[16] Dulaimi E, Uzzo RG, Greenberg RE,et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel[J]. Clin Cancer Res, 2004, 10(6):1887-93
[17] Kawamoto K, Enokida H, Gotanda T, et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer[J]. Biochem Biophys Res Commun, 2006, 339(3):790-796
[18] Friedrich MG, Chandrasoma S, Siegmund KD, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma[J]. Eur J Cancer, 2005, 41(17):2769-2778
[19] Kim WJ, Kim EJ, Jeong P, et al.RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors[J]. Cancer Res, 2005, 65(20): 9347-9354
[20]元云飞,李锦清,杨祖立,等.肿瘤相关基因过甲基化的研究进展[J].癌症, 2002,21(11):1267-1277
[21] Moh, M C, TIAN Q, Zhang T, et al. The immunoglobulin-like cell adhesion molecule hepaCAM modulates cell adhesion and motility through direct interaction with the actin cytoskeleton[J]. Journal of Cell physiology 2009, 219(2):382-391.
[22]荀春华,罗春丽,吴小候,等. HepaCAM基因转染对肾癌细胞侵袭活性的影响[J].肿瘤,2008,28(12):1029-1033
[23] Horikawa Y, Sugano K, Shigyo M, et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ[J]. J Urol 2003, 169(4):1541-1545
[24] Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy[J]. Nature, 2004, 429(6990):457-463
[1] Vertino PM ,Yen RW, Gao J ,et al. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA(cytosine- 5) - methyltransferase1. Mol Cell Biol ,1996 ,16 (8) ;45-55
[2] Bird A. DNA methylation patterns and epigenetic memory[J].Genes Dev,2002,16 (1):6-21
[3] Siyang Zhang, Dawei Guo, Lili Jiang, et al. SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC Cancer, 2008, 8: 150
[4]彭正良.甲状腺肿瘤相关基因甲基化研究进展.国外医学·生理、病理科学与临床分册.2005,25(2):126-129
[5] Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression [J]. Nature, 2004,432 (7015 ):307-315
[6] Chan MW, Chan LW,et a1. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients[J].Int J Cancer. 2003,104(5):611-615
[7]米军,段建敏,岳中瑾,等.膀胱癌DBCCR1、p16、p15、p14基因甲基化检测的意义[J].中华泌尿外科杂志,2006,27(6):427-429
[8] Hellwinkel, Merab Kedia, Hendrik Isbarn, et a1. Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours[J]. Bju International,2007,101:753–757.
[9] Horikawa Y, Sugano K, Shigyo M.et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ[J]. J Urol. 2003 ,169(4):1541-1545
[10] Ribeiro-Filho LA, Franks J, Sasaki M, et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer[J]. Mol Carcinog, 2002, 34(4):187-198
[11] Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res, 2005,65(20):9347-9354
[12] Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylationprofile of bladder cancer and its relationship to clinicopathological features [J]. Cancer Res,2001,61(24) ;8659-8663
[13] Aleman A, Adrien L, Lopez-Serra L,et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays[J]. Br J Cancer, 2008, 98(2):466-473
[14] Chan MW, Chan LW, Tang NL, et al. Hypermethyaltion of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients[J]. Clin. Cancer Res, 2002,8(2) ;464-470
[15] Sathyanarayana UG, Maruyama R, Padar A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes[J]. Cancer Res, 2004, 64 (4) :1425 -1430
[16] Urakami S, Shiina H, Enokida H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection[J]. Clin.Cancer Res,2006,12(7Pt 1) :2109-2116
[17] Kang GH, Lee S, Kim JS, et a1. Profile of aberrant CpG island methyhlation along the multistep pathway of gastric carcinogenesis[J]. Lab Invest, 2003, 83(5):635-641
[18] Czerniak B, Herz F, Wersto RP, Koss LG. Asymmetric distribution of oncogene products at mitosis[J]. Proc.Natl Acad. Sci. USA,1992,82(11):4860-4863
[19] Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene[J]. N.Engl.J.Med,1993,329(18):1318-1327
[20] Al-Sukhun S, Hussain M, Molecular biology of transitional cell carcinoma[J]. Crit.Rev.Oncol.Hematol,2003 ,47(2):181-193
[21] Orntoft TF, Wolf H. Molecular alterations in bladder cancer[J]. Urol. Res, 1998, 26 (4):223-233
[22] Jones PA, Baylin SB. The fundamental role of epigenetic events in cacer[J]. Nat.Rev.Genet,2002,3(6):415-428
[23] Jones PA, Larid PW. Cancer epigenetics comes of age [J]. Nat. Genet. 1999, 21 (2): 163-167
[24] Herman JG, Baylin SB.Gene silencing in cancer in association with promoter hypermethylation[J]. N.Engl.J.Med,2003,349(21):2042-2054
[25] Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor [J]. J.Urol, 2008, 180 (3): 1141-1145.
[26] Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients[J]. Clin. Cancer Res,2003,10(22):7457-7465
[27] Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methyaltion of multiople genes in urine DNA and bladder cancer detection[J].J.Natl Cancer Inst,2006,98(14):996-1004
[28] Yates DR, Rehman I,Meuth M,Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign contrls[J]. Oncogene,2006,25(13):1984-1988